PRTA241220C22500
- 2.60
- +1.00+62.50%
Prothena Newsroom
Prothena Corp Analyst Ratings
RBC Capital Maintains Prothena(PRTA.US) With Hold Rating, Maintains Target Price $24
H.C. Wainwright Maintains Prothena(PRTA.US) With Buy Rating, Maintains Target Price $84
Prothena's Strategic Advancements and Financial Strength Underpin Buy Rating
Express News | Prothena Corporation PLC: Expect FY2024 Net Cash Used in Operating & Investing Actives to Be $148 to $160 Mln
Earnings Flash (PRTA) PROTHENA CORPORATION Reports Q3 Revenue $970,000
Prothena | 10-Q: Q3 2024 Earnings Report
Prothena Corp Q3 2024 GAAP EPS $(1.10) Beats $(1.18) Estimate, Sales $970.00K Miss $1.23M Estimate
Express News | Prothena Q3 Operating Expenses USD 67.483 Million
Press Release: Prothena Reports Third Quarter 2024 Financial Results and Business Highlights
Prothena 3Q Loss/Shr $1.10 >PRTA
Here Are the Major Earnings After the Close Today
Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?
Earnings Preview For Prothena Corp
Earnings Preview: Prothena to Report Financial Results Post-market on November 12
$Prothena(PRTA.US)$ is scheduled to release its financial results post-market on November 12 ET. Earnings PreviewAnalysts estimate $Prothena(PRTA.US)$ to post revenue of USD600.00K for 2024Q3, down 99
Prothena to Report Third Quarter 2024 Financial Results on November 12
Prothena's (NASDAQ:PRTA) Growing Losses Don't Faze Investors as the Stock Advances 9.0% This Past Week
Strength Seen in Prothena (PRTA): Can Its 15.0% Jump Turn Into More Strength?
Prothena Up Nearly 17%, on Pace for Largest Percent Increase Since October 2023 -- Data Talk
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday